Investor Relations

About Us

Scope Fluidics S.A., a constituent of the sWIG80 and WIGmed stock market indices, is a life science company engaged in developing cutting-edge technologies for the medical diagnostics and healthcare markets. It has demonstrated its global potential by completing the largest transaction to date in the Polish life science sector: the sale of the PCR|ONE system to US-based Bio-Rad Laboratories for a total of USD 130 million. Scope Fluidics operates under a Venture Studio model – identifying worldwide challenges and market opportunities, and transforming them into concepts for breakthrough products. Its focus lies in healthcare, where it applies a rigorous process for selecting and developing projects with strong commercial prospects globally. The Company’s strategy is to create value by bringing projects to maturity and executing strategic transactions, including sales to international medtech operators. Its most advanced project currently under development is BACTEROMIC, a rapid, automated Antibiotic Susceptibility Testing (AST) system, which provides precise, actionable insights to guide the selection of effective antibiotic therapies, combining high performance with ease of use. Results from the Early Access Programme (EAP) confirm both the system’s readiness for broader market launch and its significant competitive advantages. In addition, the Scope Fluidics Group is advancing two early-stage projects: 1) EDOCERA – a system designed for the rapid diagnosis of stroke, enabling immediate medical intervention, and 2) HYBOLIC – a system intended for the early detection of metabolic syndrome risks, including insulin resistance and type 2 diabetes, by monitoring key biomarkers such as insulin and glucose levels.

See More

Strategy and Business Model

Every project begins with the identification of unmet needs in the life science sector. Next, Scope Fluidics develops an innovative solution that is subject to ongoing technical and commercial validation from the very outset of the project. The development is driven by a dedicated team of in-house experts and scientists with knowledge spanning microbiology, biochemistry, manufacturing, physics, IT, and engineering. Collaboration with external specialists can further strengthen this process. Projects are developed within special-purpose vehicles (SPVs), controlled by Scope Fluidics. A new concept originates at the Company and, once it is ready to advance, an SPV is established to carry the project forward. The original team members transfer to the SPV, ensuring continuity of expertise and vision. As the project progresses, the team expands in line with its growing needs. From conception through execution, development is collaborative and solution-focused, addressing challenges at every stage of the process. The ultimate goal is a strategic sale. The target model involves the transfer of all shares in the SPV along with its assets – including intellectual property, certifications, and technology. However, the Company remains flexible as to the timing of the sale, allowing for staged commercialisation if appropriate. Strategic transactions are expected to generate value for shareholders through the payment of dividends. By following this model, Scope Fluidics ensures that proven methodologies, best practices, and processes can be leveraged across multiple projects, enhancing operational efficiency. This approach also maximises the chance of success for subsequent ventures.

See More
Projekt rurociągów
Strategia i model biznesowy

Strategy and Business Model

Every project begins with the identification of unmet needs in the life science sector. Next, Scope Fluidics develops an innovative solution that is subject to ongoing technical and commercial validation from the very outset of the project. The development is driven by a dedicated team of in-house experts and scientists with knowledge spanning microbiology, biochemistry, manufacturing, physics, IT, and engineering. Collaboration with external specialists can further strengthen this process. Projects are developed within special-purpose vehicles (SPVs), controlled by Scope Fluidics. A new concept originates at the Company and, once it is ready to advance, an SPV is established to carry the project forward. The original team members transfer to the SPV, ensuring continuity of expertise and vision. As the project progresses, the team expands in line with its growing needs. From conception through execution, development is collaborative and solution-focused, addressing challenges at every stage of the process. The ultimate goal is a strategic sale. The target model involves the transfer of all shares in the SPV along with its assets – including intellectual property, certifications, and technology. However, the Company remains flexible as to the timing of the sale, allowing for staged commercialisation if appropriate. Strategic transactions are expected to generate value for shareholders through the payment of dividends. By following this model, Scope Fluidics ensures that proven methodologies, best practices, and processes can be leveraged across multiple projects, enhancing operational efficiency. This approach also maximises the chance of success for subsequent ventures.

See More

Funding

Scope Fluidics manages each project only during its early stages, up to the point when it is transferred for execution to a dedicated special-purpose vehicle (SPV). However, the Management Board remains unchanged, with identical representation at both the Company and its SPVs, ensuring aligned leadership and oversight. Project funding is secured both by Scope Fluidics and by the SPVs. The Company raises capital through equity offerings and debt financing, including facilities provided by the European Investment Bank. The SPVs, in turn, seek to access grants and subsidies. Scope Fluidics also plays a key role in attracting external investors to acquire partial or full ownership stakes in the SPVs. Project teams within the respective subsidiaries are also actively involved in this process.

Intellectual Property

One of the core strengths of Scope Fluidics and its Group lies in consistent and proactive protection of intellectual and industrial property related to their developed innovations. Currently, the Company holds a patent for elements of its proprietary microfluidic technology, as well as four registered trademarks. In addition, each subsidiary independently manages and protects its own industrial property portfolio. Bacteromic Sp. z o.o., for instance, maintains five patent families, which collectively include two granted patents and ten pending patent applications, safeguarding the company’s technological solutions. A patent family is defined as a collection of individually protected elements within a given solution – such as specific components of a cartridge or analyser, ensuring comprehensive protection.

Our Companies

BACTEROMIC – Unique diagnostic solutions

BACTEROMIC is a diagnostic system designed to address one of the most pressing challenges in modern medicine – that of antimicrobial resistance. The system enables phenotypic assessment of the effectiveness of antibiotics used to treat various infections, such as those affecting the respiratory tract, bloodstream, urinary tract, or skin. It also has the capability to detect resistance mechanisms, providing clinicians with deeper insight into bacterial behaviour and treatment options. Thanks to the determination and expertise of a multidisciplinary team of biotechnologists, engineers and software developers – combined with an innovative approach to contemporary diagnostics – Scope Fluidics has created a device with enormous market potential, one that can revolutionise antibiotic therapy. Each test simultaneously analyses 640 independent bacterial cultures, offering unmatched diagnostic power in a single run.

Maszyna Bacteromic

EDOCERA

EDOCERA is developing a cutting-edge system for real-time stroke prevention and diagnosis. The solution combines a monitoring device with AI-powered software that continuously tracks a patient’s vital health parameters. Using sophisticated algorithms, the system detects critical changes that indicate a heightened risk of stroke and immediately issues an alert. By shortening reaction times, EDOCERA enables faster initiation of appropriate treatment, thereby reducing the severity of long-term consequences of stroke. This innovation not only improves patient safety but also brings peace of mind to individuals at risk and their families.

HYBOLIC

HYBOLIC is focused on developing a next-generation system for the early detection of diabetes and related metabolic disorders. The solution is intended integrate a biomarker monitoring device with intelligent software that will analyse concentrations of key molecules, such as glucose and insulin. With the aid of advanced algorithms, the system aims to identify early warning signals of insulin resistance, potentially years before symptoms appear. By enabling earlier diagnosis, HYBOLIC will support proactive health management and empower users to take informed steps to protect their metabolic well-being. Early detection improves treatment outcomes and allows the implementation of effective preventive strategies. Ultimately, HYBOLIC will help users maintain better control over their health, enhancing both safety and quality of life.

OUR TEAM 

Scope Fluidics brings together a diverse team of highly-skilled professionals with expertise spanning biochemistry, microbiology, physics, engineering, law, marketing, business development, finance, human resources, and project management. The Group’s strategic direction is set by a three-member Management Board, whose composition reflects the Company’s dual commitment to scientific excellence and sound business leadership.

Piotr Garstecki

Piotr Garstecki

President of the Board

Marcin Izydorzak

Marcin Izydorzak

Vice President of the Management Board

Szymon Ruta

Szymon Ruta

Vice President of the Management Board – Chief Financial Officer

Robert Przytuła

Chairman of the Supervisory Board

Andrzej Chądzyński

Member of the Supervisory Board

Robert Hołyst

Member of the Supervisory Board

Patryk Mikucki

Member of the Supervisory Board

Karolina Radziszewska

Member of the Supervisory Board

Joanna Rzempała

Member of the Supervisory Board

Professor Carl Wittwer

Professor Wilhelm Huck

Sarai Kemp

Dr Vincent Linder

Professor David Weitz

Dr Agnieszka Sulikowska

OUR AWARDS

The company has won numerous awards confirming its innovation and effectiveness:

Newsletter

Stay up to date with the latest information.